• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 5. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Peptides
• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Peptides

Met-Enkephalin-Arg-Phe Amide (CAS No. 78761-61-2): A Comprehensive Overview

Met-enkephalin-arg-phe amide, also known as H-Tyr-Gly-Gly-Phe-Met-Arg-Phe-NH2, is a synthetic peptide that has garnered significant attention in the fields of neuroscience and pharmacology. This compound, identified by the CAS registry number 78761-61-2, is a derivative of the naturally occurring enkephalins, which are endogenous opioid peptides involved in pain modulation and neurotransmission. The addition of arginine and phenylalanine residues to the N-terminal of the peptide enhances its bioactivity and stability, making it a promising candidate for therapeutic applications.

The structure of met-enkephalin-arg-phe amide consists of seven amino acids: histidine (H), tyrosine (Tyr), glycine (Gly), phenylalanine (Phe), methionine (Met), arginine (Arg), and another phenylalanine (Phe), terminated by an amide group (-NH2). This specific sequence allows the peptide to interact with opioid receptors, particularly the μ-opioid receptor (MOR), which is central to its analgesic effects. Recent studies have highlighted the potential of this compound in treating chronic pain conditions, such as neuropathic pain and inflammatory arthritis, due to its ability to modulate both acute and persistent pain pathways.

One of the most notable advancements in research involving CAS No. 78761-61-2 is its role in neuroprotection. Preclinical studies have demonstrated that this peptide can mitigate neuronal damage caused by ischemia-reperfusion injury, a condition often observed in stroke patients. The neuroprotective effects are attributed to its ability to reduce oxidative stress and inhibit pro-inflammatory cytokines, thereby preserving neuronal integrity. These findings suggest that met-enkephalin-arg-phe amide could be a novel therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition to its therapeutic potential, CAS No. 78761-61-2 has been extensively studied for its pharmacokinetic properties. Research indicates that the peptide exhibits good bioavailability when administered via certain routes, such as subcutaneous injection or nasal delivery. However, challenges remain in optimizing its delivery methods to enhance efficacy and reduce systemic side effects. Recent innovations in drug delivery systems, including lipid nanoparticles and polymeric micelles, are being explored to address these limitations.

The latest research on H-Tyr-Gly-Gly-Phe-Met-Arg-Phe-NH2 also points to its potential as an anti-addictive agent. By selectively targeting certain opioid receptor subtypes, this compound may offer a safer alternative to traditional opioids, which are associated with high risks of dependence and overdose. Clinical trials are currently underway to evaluate its safety profile and efficacy in managing opioid use disorder.

In conclusion, CAS No. 78761-61-2, or met-enkephalin-arg-phe amide, represents a significant advancement in peptide-based drug development. Its dual roles as an analgesic and neuroprotective agent make it a versatile compound with broad therapeutic applications. As research continues to uncover its mechanisms of action and optimize its delivery methods, this peptide holds great promise for addressing unmet medical needs in pain management and neurodegenerative diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)